Search results
Results From The WOW.Com Content Network
Researchers further estimated that the statin recommendations for U.S. adults would drop from 45.4 million to 28.3 million with a change from PCEs to PREVENT equations. They also noted that many ...
Medical uses. Statins are usually used to lower blood cholesterol levels and reduce risk for illnesses related to atherosclerosis, with a varying degree of effect depending on underlying risk factors and history of cardiovascular disease. [16] Clinical practice guidelines generally recommend people start with lifestyle modification through a ...
Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. [1] It is a form of hyperlipidemia (high levels of lipids in the blood), hyperlipoproteinemia (high levels of lipoproteins in the blood), and dyslipidemia (any abnormalities of lipid and lipoprotein levels in the blood). [1]
JUPITER was a randomized double-blind placebo-controlled study investigating the use of rosuvastatin in the primary prevention of cardiovascular disease. The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP).
The 2024 Guideline for the Primary Prevention of Stroke also ... and gender-specific recommendations are important additions to guiding clinical practice in an evidence-driven matter,” he told ...
Two review studies published in October 2024 highlight that vegetarian and vegan diets can be beneficial for individuals with type 2 diabetes and may lower heart disease risk across the general ...
Rosuvastatin, sold under the brand name Crestor among others, is a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. [6] It is recommended to be used together with dietary changes, exercise, and weight loss. [6] It is taken orally (by mouth).
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.